Old Compound In Cancer Treatment Proves Effective In Pediatric Neuroblastoma Models

The compound, α-difluoromethylornithine or DFMO, targets the activity of a specific enzyme and, even in very limited doses, is effective in protecting against the malignancy in animal models. The study was published in the January 15, 2009 issue of the journal, Cancer Research (Volume 69, Issue 2). “The drug, which was developed as a cancer therapy and later shelved because of toxicity concerns, has been around since the 1970s,” said John Cleveland, Ph.D.

More: continued here

Filed under: Biology on January 19th, 2009